5 Best Biotech Penny Stocks to Invest In
Ocean Biomedical, Inc. (NASDAQ:OCEA) is a biopharmaceutical company that focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases.
Pieris Pharmaceuticals Inc. (PIRS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 257,626 | $4,312,659 | 0.12% | |
| 2. | ADAR1 Capital Management Daniel Schneeberger | 144,641 | $2,398,148 | 0.39% | |
| 3. | Lynx1 Capital Management Weston Nichols | 37,436 | $620,689 | -14% | 0.21% |
| 4. | Renaissance Technologies Jim Simons | 32,171 | $533,395 | +181% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 11,686 | $195,623 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.00 | 1 | Director | 1 | 2024-08-07 | Filing | |
| $15.88 | 757 | Large Shareholder | 15,067 | 2024-08-12 | Filing | |
| $15.88 | 2,243 | Large Shareholder | 129,574 | 2024-08-12 | Filing | |
| $14.89 | 3,000 | Large Shareholder | 127,331 | 2024-08-09 | Filing | |
| $0.85 | 10,000 | 20,000 | 2023-05-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.15 | 29,200 | 4,638 | 2021-08-30 | Filing | ||
| $5.00 | 9,200 | 33,838 | 2021-08-30 | Filing | ||
| $2.95 | 1,900,000 | Large Shareholder | 3,675,530 | 2020-07-21 | Filing | |
| $4.50 | 1,128 | Large Shareholder | 314,139 | 2019-09-06 | Filing | |
| $4.50 | 25,720 | Large Shareholder | 2,233,074 | 2019-09-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 55.2,625 | $317,605 | 0.34% | |
| 2. | 12,971.8,375 | $188,870 | 0% | |
| 3. | 11,342.375 | $165,145 | 0% | |
| 4. | 9,518.05 | $138,625 | 0% | |
| 5. | 9,375 | $136,500 | 0.11% |
News See All
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen. And welcome to the Pieris Pharmaceuticals to host First Quarter 2023 Investor Call.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript
Operator: Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Conference Call and Webcast. . A question-and-answer session will follow the formal presentation.
5 Cheap Small-Cap Stocks to Buy
VEON Ltd. (NASDAQ: VEON) is a Dutch telecommunication and digital services company that offers services in telecommunication, voice, broadband, and wireless internet.
5 Best Biotech Penny Stocks to Buy Now
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is a Boston-based biopharma firm founded in 2018. It is placed fifth on our list of 10 best biotech penny stocks to buy now.
Is PIRS A Good Stock To Buy Now?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
25 Best U.S. Cities to Live With Asthma
Navigating through life with asthma can be a life-long challenge in itself. Sometimes it becomes very important to constantly monitor your surroundings to detect any triggers.
Hedge Funds Are Crazy About Pieris Pharmaceuticals, Inc. (PIRS)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Did Hedge Funds Make The Right Call On Pieris Pharmaceuticals, Inc. (PIRS) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Is Pieris Pharmaceuticals, Inc. (PIRS) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.